|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Virtual Journal Club IO | **Project Code** | PI4LGR034 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey Goins |
| **Compliance- Briana** | Briana Devaser | **Editor** | Choose an item. |

**Launch Date/Internal Launch Date:  
December 2014**

**This needs to be listed on both the online education and Immuno-Oncology pages**

**Project Type**

Virtual Journal Club

Downloadable Slides

Other: Link to Manuscript

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities: Oncology Guru

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:  
Immun-Onc Journal Club**

**Listing Page**

**[Insert small VJC Graphic to the left]**

**[TITLE]**Virtual Journal Club**:** Immuno-Oncology Comes of Age

**[DATE]**November 2014

**Landing Page**

**[Insert VJC Banner Here]**

**Banner Text**

**Orange: prIME ONCOLOGY VIRTUAL JOURNAL CLUB**

**White: Immuno-Oncology Comes of Age**

**Activity Features**

* Expert Discussion
* Downloadable Slides
* CME-Certified

**[Insert Screenshots]**

**Activity Overview**

This CME-certified independent medical education activity features an expert interview withJeffrey S. Weber, MD, PhD, and Janice Galleshaw, MD, focusing on the evolution of immunotherapy as a treatment for cancer.

Drs Weber and Galleshaw discuss a recent supplement to *Seminars in Oncology,* titled “Immuno-Oncology Comes of Age.” *Seminars in Oncology.* 2014;41(Suppl 5): S1-S40. [[http://www.seminoncol.org/issue/S0093-7754%2814%29X0011-4]]

**Featured Experts**

**[Insert Photo] Jeffrey S. Weber, MD, PhD**

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States

**[Insert Photo] Janice Galleshaw, MD** Senior Medical Director  
 prIME Oncology

**Target Audience**

This CME-activity is specifically designed to meet the needs of practicing medical oncologists, hematologists/oncologists, oncology nurses, and other healthcare professionals involved in the treatment of patients with cancer.

**Learning Objectives**

After successful completion of this educational activity, participants should be able to:

* Explain the rationale for investigating immunotherapies for the treatment of cancer
* Analyze approved and emerging immunotherapies, including checkpoint blockade inhibitors and immunostimulatory vaccines
* Describe future directions for immunotherapy, including novel approaches to immunotherapy and use of immunotherapy-based combinations

**Provider**

This activity is provided by prIME Oncology.

**Continuing Medical Education**prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of XX*AMA PRA Category 1 Credits*™*.*Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**SUPPORT**

This educational activity is supported by a grant from Merck & Co., Inc. **[NO LOGOS]**

**CME PAGE**

**Activity Date**

Release Date

December X, 2014

Expiration Date

December X, 2015

**[Refer to content above for these titles]**

**Overview  
Target Audience**

**Learning Objectives**

**Provider**

**Continuing Medical Education  
Support Statement**

**Method of Participation**  
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.   
  
Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)  
  
Links to the posttest are available on the video player pages.   
  
In order to claim credit for this activity, a score of XX% or higher is required.

**Disclosure of Conflicts of Interest**prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Weber has disclosed that he has received consulting fees from Bristol Myers Squibb, Genentech and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Chelsey Goins, PhD (clinical content planner/reviewer) – no relevant financial relationships
* Janice Galleshaw, MD (clinical content reviewer) – no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

**Disclosure of Unlabeled Use**This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**Player Page**

**[Insert VJC Banner Here]**

[Video player and slides]

**[Insert text: Click the thumbnails above to advance through the reference deck.]**

**[Insert buttons: Download Slides and Evaluate and Claim Credit]**

**[Refer to content above for these titles]**

**Activity Overview**

**Featured Experts**

**Support**